Iqvia Holdings Inc (IQV) Stock Price, Quote & News

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions th...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 919 998 2000

Website: www.iqvia.com

Address:

2400 Ellis Road, Durham, United States

UgoGreg Feb. 14 at 4:44 PM

$IQV https://youtu.be/m61diFB2Pag

0 · Reply

Estimize Feb. 9 at 3:06 PM

Wall St is expecting 2.84 EPS for $IQV Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont

0 · Reply

ZacksResearch Feb. 5 at 5:52 PM

$IQV just delivered a clean Q4 beat — and guidance is turning heads 👀 Q4 2025 earnings and revenues topped estimates with double-digit Y/Y sales growth, driven by strong segment gains, alongside upbeat 2026 revenue guidance. See what this could mean next 👉 https://www.zacks.com/stock/news/2830156/iqvia-q4-earnings-revenues-beat-estimates-increase-yy?cid=sm-stocktwits-2-2830156-teaser-32194&ADID=SYND_STOCKTWITS_TWEET_2_2830156_TEASER_32194

0 · Reply

ZacksResearch Feb. 5 at 4:52 PM

$IQV crushes Q4 earnings & revenue estimates! 📈 💰 Adjusted EPS jumped 9.6% YoY to $3.42, outpacing the Zacks Consensus Estimate. 📊 Total revenues rose 10.3% YoY to $4.4B, beating estimates by 2.8%. 🚀 Strong segmental growth drives performance, with R&D and Tech segments meeting expectations while Contract Sales and Medical Solutions surpassed them. Discover what's fueling IQVIA's momentum 👉 https://www.zacks.com/stock/news/2830156/iqvia-q4-earnings-revenues-beat-estimates-increase-yy?cid=sm-stocktwits-2-2830156-body-32157&ADID=SYND_STOCKTWITS_TWEET_2_2830156_BODY_32157

0 · Reply

1986iamwallstreet Feb. 5 at 2:38 PM

$IQV flush city 🩸🩸🩸🩸🩸🩸

0 · Reply

StocktwitsEarnings Feb. 5 at 12:11 PM

$IQV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $3.02 up 23.77% YoY • Reported revenue of $4.36B up 10.26% YoY • For full-year 2026, IQVIA expects revenue between $17.15B to $17.35B, Adjusted EBITDA from $3.98B to $4.03B, and Adjusted Diluted Earnings per Share of $12.55 to $12.85.

0 · Reply

1986iamwallstreet Feb. 5 at 12:09 PM

$IQV IQVIA Hldgs Sees FY2026 Adj EPS $12.55-$12.85 vs $12.95 Est; Sees Sales $17.150B-$17.350B vs $17.071B Est 🩸🩸🩸🩸🩸🩸🩸

0 · Reply

AlgorithmAdvisors Feb. 4 at 11:30 AM

$IQV is a leading CRO facing biotech funding headwinds; backlog conversion and large pharma demand provide stability.

0 · Reply

ZacksResearch Feb. 3 at 5:13 PM

Earnings setup for $IQV — growth expectations are heating up 📈 IQV is set to report fourth-quarter 2025 earnings on Feb. 5, with revenues expected to rally 7.2% year over year to $4.2B and EPS expected to rise 9% on segment growth. Full earnings preview and key details here 👉 https://www.zacks.com/stock/news/2828079/iqvia-set-to-report-q4-earnings-heres-what-you-should-know?cid=sm-stocktwits-2-2828079-teaser-31718&ADID=SYND_STOCKTWITS_TWEET_2_2828079_TEASER_31718

0 · Reply

ZacksResearch Feb. 3 at 4:13 PM

$IQV set to report Q4 earnings — will it continue its growth trend? 📊 IQVIA has surpassed the Zacks Consensus Estimate in the last four quarters, averaging a 1.6% surprise. For Q4, revenue is expected to grow 7.2% YoY, with EPS estimated at $3.4, a 9% increase. Discover the full earnings preview here 👉 https://www.zacks.com/stock/news/2828079/iqvia-set-to-report-q4-earnings-heres-what-you-should-know?cid=sm-stocktwits-2-2828079-body-31719&ADID=SYND_STOCKTWITS_TWEET_2_2828079_BODY_31719

0 · Reply

Oakmark Global All Cap Strategy Q4 2025 Performance Review

BABA CNH

Feb 10, 2026, 8:00 AM EST - 6 days ago

IQVIA and Duke Clinical Research Institute Announce Strategic Collaboration to Advance Clinical Research in Obesity and Related Conditions

Feb 5, 2026, 3:24 PM EST - 11 days ago

IQVIA Holdings Inc. (IQV) Q4 2025 Earnings Call Transcript

Feb 5, 2026, 9:07 AM EST - 11 days ago

IQVIA forecasts weak annual profit on higher interest expenses

Feb 5, 2026, 7:00 AM EST - 11 days ago

IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Jan 29, 2026, 8:00 AM EST - 18 days ago

IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration

Jan 22, 2026, 4:05 PM EST - 25 days ago

IQVIA Named to the Fortune® World's Most Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year

Jan 20, 2026, 4:45 PM EST - 27 days ago

IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026

Dec 11, 2025, 1:56 PM EST - 2 months ago

IQVIA: Increasingly Indispensable In Drug Development

Dec 2, 2025, 8:00 AM EST - 2 months ago

IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform

Nov 12, 2025, 5:43 AM EST - 3 months ago

Oakmark Global Concentrated Strategy Q3 2025 Top Contributors And Detractors

BABA CHTR CNC CNH GOOG GOOGL

Nov 11, 2025, 2:31 PM EST - 3 months ago

IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 2:15 AM EST - 3 months ago

Oakmark Concentrated Strategy: 6 Stocks That Raised Guidance And Drove Innovation

CRM GOOG GOOGL KDP MOH WBD

Nov 5, 2025, 4:15 PM EST - 3 months ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Oct 28, 2025, 1:52 PM EDT - 3 months ago

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:53 AM EDT - 3 months ago

IQVIA narrows annual profit forecast amid continued research contract cancellations

Oct 28, 2025, 7:00 AM EDT - 3 months ago

IQVIA Reports Third-Quarter 2025 Results

Oct 24, 2025, 4:30 AM EDT - 4 months ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IVZ JNJ LRCX

Oct 21, 2025, 4:15 PM EDT - 4 months ago

IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025

Sep 30, 2025, 4:15 PM EDT - 4 months ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 26, 2025, 9:40 AM EDT - 5 months ago

ILMN Stock vs. IQV Stock

ILMN

Sep 16, 2025, 8:00 AM EDT - 5 months ago

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

Sep 11, 2025, 2:00 AM EDT - 5 months ago

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Sep 10, 2025, 8:00 AM EDT - 5 months ago

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

Sep 2, 2025, 9:41 AM EDT - 5 months ago

IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:00 AM EDT - 5 months ago

IQVIA Announces CFO Transition in Early 2026

Aug 28, 2025, 8:00 AM EDT - 6 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX MRNA SANA

Aug 19, 2025, 12:00 PM EDT - 6 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW

Aug 18, 2025, 9:00 AM EDT - 6 months ago

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

VEEV

Jul 22, 2025, 5:40 PM EDT - 7 months ago

IQVIA: Q2 Earnings Exceeded My Expectations

Jul 22, 2025, 2:00 PM EDT - 7 months ago

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 8:42 AM EDT - 7 months ago

IQVIA beats quarterly estimates on resilient demand for healthcare analytics

Jul 22, 2025, 7:00 AM EDT - 7 months ago

IQVIA Reports Second-Quarter 2025 Results

Jul 16, 2025, 7:54 AM EDT - 7 months ago

IQVIA: Competition Is Creating More Challenges Over The Long Haul

Jul 1, 2025, 7:00 AM EDT - 8 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jun 16, 2025, 9:00 AM EDT - 8 months ago

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'

Jun 11, 2025, 7:00 AM EDT - 8 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 10, 2025, 2:23 PM EDT - 8 months ago

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

Jun 2, 2025, 4:37 PM EDT - 9 months ago

IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 9 months ago

IQVIA Announces Offering of Senior Notes

May 27, 2025, 7:00 AM EDT - 9 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

RNTX

May 16, 2025, 8:00 AM EDT - 9 months ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 9, 2025, 1:48 PM EDT - 10 months ago

IQVIA: Q1 Earnings Support Steady Optimism

May 7, 2025, 4:15 PM EDT - 10 months ago

IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

May 6, 2025, 3:04 PM EDT - 10 months ago

IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:00 AM EDT - 10 months ago

IQVIA Reports First-Quarter 2025 Results

Apr 28, 2025, 9:00 AM EDT - 10 months ago

IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

Apr 23, 2025, 9:00 AM EDT - 10 months ago

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

Apr 21, 2025, 4:15 PM EDT - 10 months ago

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Apr 15, 2025, 8:00 AM EDT - 10 months ago

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

UgoGreg Feb. 14 at 4:44 PM

$IQV https://youtu.be/m61diFB2Pag

0 · Reply

Estimize Feb. 9 at 3:06 PM

Wall St is expecting 2.84 EPS for $IQV Q1 [Reporting 04/23 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont

0 · Reply

ZacksResearch Feb. 5 at 5:52 PM

0 · Reply

ZacksResearch Feb. 5 at 4:52 PM

0 · Reply

1986iamwallstreet Feb. 5 at 2:38 PM

$IQV flush city 🩸🩸🩸🩸🩸🩸

0 · Reply

StocktwitsEarnings Feb. 5 at 12:11 PM

0 · Reply

1986iamwallstreet Feb. 5 at 12:09 PM

$IQV IQVIA Hldgs Sees FY2026 Adj EPS $12.55-$12.85 vs $12.95 Est; Sees Sales $17.150B-$17.350B vs $17.071B Est 🩸🩸🩸🩸🩸🩸🩸

0 · Reply

AlgorithmAdvisors Feb. 4 at 11:30 AM

$IQV is a leading CRO facing biotech funding headwinds; backlog conversion and large pharma demand provide stability.

0 · Reply

ZacksResearch Feb. 3 at 5:13 PM

0 · Reply

ZacksResearch Feb. 3 at 4:13 PM

0 · Reply

OfficialStocktwitsUser Jan. 27 at 5:51 PM

$IQV RSI: 52.50, MACD: 3.5067 Vol: 6.23, MA20: 237.23, MA50: 229.22 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AcceleratorModel Jan. 23 at 6:10 AM

$IQV may be time to come back for more

0 · Reply

AcceleratorModel Jan. 23 at 5:31 AM

$IQV Been choppy — but ultimately up and to the right for this name. Haven’t touched it since July ‘25 earnings for a 14% 1 day return. Not looking for a hockey stick here, just a continuation

0 · Reply

rottieluvr3 Jan. 16 at 7:43 PM

$IQV This recently broke resistance, but just barely. Once there is confirmation of a breakout, I’m a buyer.

1 · Reply

ZacksResearch Jan. 15 at 3:26 PM

Data is becoming the next profit engine in medtech — and these names are leading the charge. 📊🧠 $MDT, $IQV and $GEHC are showing how analytics, AI, and enterprise data platforms can be monetized into recurring revenue streams, pushing medical devices beyond just hardware. See how data + AI are reshaping revenue models in medtech 👉 https://www.zacks.com/stock/news/2818016/3-medical-device-companies-in-focus-for-monetizing-data-and-analytics?cid=sm-stocktwits-2-2818016-teaser-29098&ADID=SYND_STOCKTWITS_TWEET_2_2818016_TEASER_29098

0 · Reply

SuperGreenToday Jan. 14 at 7:33 PM

$IQV Share Price: $241.99 Contract Selected: Aug 21, 2026 $250 Calls Buy Zone: $18.02 – $22.26 Target Zone: $32.32 – $39.50 Potential Upside: 69% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BillionerOfKing Jan. 14 at 10:14 AM

$IQV Current Stock Price: $241.63 Contracts to trade: $240 IQV Jan 16 2026 Call Entry: $2.16 Exit: $3.17 ROI: 47% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Philox Jan. 8 at 2:02 PM

$IQV just popped up on my possible call screen! Not sure on this one as it seems to have liquidity issues but it is on an uptrend. Anyone have any opinions?

0 · Reply

OfficialStocktwitsUser Dec. 30 at 5:10 AM

$IQV RSI: 55.89, MACD: 1.5703 Vol: 2.61, MA20: 224.22, MA50: 220.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Dec. 29 at 6:24 PM

$IQV just ripped higher — and this move looks earned, not hype. 🚀 IQVIA Holdings shares are up 25.5% in three months, driven by its AWS partnership, a growing R&DS backlog, and buybacks that are lifting its earnings outlook — a powerful combo for confidence. See why retaining IQV stock makes sense right now 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-teaser-26674&ADID=SYND_STOCKTWITS_TWEET_2_2809908_TEASER_26674

0 · Reply

ZacksResearch Dec. 29 at 5:24 PM

$IQV: Is this a buy with 25.5% gains over the past three months compared to the industry’s 12.1% rise? 📈 🤝 Partnership with AWS enhances its AI capabilities in life sciences, improving efficiency. 📊 R&DS backlog at $32.4B, with $8.1B set to convert in 12 months, and $2.6B in net new bookings. 💸 $1.03B in share buybacks over nine months ending in 2025 supports EPS growth. IQV carries a Zacks Rank of #3 (Hold) but faces liquidity challenges with a declining current ratio. Discover the full investment picture here 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-body-26676&ADID=SYND_STOCKTWITS_TWEET_2_2809908_BODY_26676

0 · Reply

AlgorithmAlphaV3 Dec. 25 at 5:09 AM

$IQV Downside protection weakens if discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.

0 · Reply

Market Cap	28.43B
Revenue (ttm)	16.31B
Net Income (ttm)	1.36B
EPS (ttm)	N/A
PE Ratio	15.53
Forward PE	14.61
Profit Margin	8.34%
Debt to Equity Ratio	2.37

Volume	4,265,600
Avg Vol	1,798,234
Day's Range	N/A - N/A
Shares Out	170.30M
Stochastic %K	13%
Beta	1.37
Analysts	Strong Sell
Price Target	$244.20